S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
AMLX · Amylyx Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$29.08
+0.28
(+0.99%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$29.08
$28.96
$29.73
52-WEEK RANGE
$29.08
$10.83
$41.14
What's happening
- AMLX is up 0.99% today, trading at $29.08. — Live quote
- Volume today (98,036) is well below its 3-month average of 2,150,850. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.39 actual vs. $-0.37 estimated (-5.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 7
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AMLX
+138.16%
vs S&P 500
+125.39%
1-YEAR RETURN
AMLX
+87.18%
vs S&P 500
+72.62%
6-MONTH RETURN
AMLX
+62.27%
3-MONTH RETURN
AMLX
+55.51%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.39
Est. $-0.37
MISS -5.9%
2026-04-26 (Q1 2026)
$-0.37
Est. $-0.34
MISS -9.8%
2026-01-26 (Q4 2025)
$-0.30
Est. $-0.37
BEAT +18.0%
2025-10-26 (Q3 2025)
$-0.37
Est. $-0.46
BEAT +19.4%
Valuation Measures & Ratios
Enterprise Value4$3.59B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)18.54
Price / Book78.35
EV4 / Revenue18.20
EV4 / EBITDA90.11
Profit Margin-94.56%
Operating Margin-99.16%
Return on Equity (ROE8)-52.92%
Return on Assets (ROA9)-48.53%
Avg Volume (3M)2,150,850
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.00B | $1.55B | $1.26B | $576.6M | $301.8M |
| P/E | -12.46 | -10.14 | -6.84 | -2.59 | -1.01 |
| Price/Sales | — | — | 3033.80 | -949.91 | 3.43 |
| Price/Book | 8.37 | 5.68 | 3.80 | 3.43 | 1.50 |
| EV/Revenue | — | — | 2492.50 | -854.22 | 2.75 |
| ROE | -67.12% | -56.02% | -55.55% | -132.69% | -149.00% |
| ROA | -60.68% | -52.12% | -50.85% | -114.47% | -136.61% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,666,971
Change from Prior Settlement-6.26%
% of Float—
Days to Cover (Short Ratio)9.16
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +87.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -94.6%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-07; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AMLX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $416.0K | -$1.0M | $88.6M |
| Operating income | -$45.7M | -$43.8M | -$36.0M | -$42.9M | -$37.8M | -$75.7M | -$76.3M | -$122.1M |
| Net income | -$43.4M | -$41.3M | -$34.4M | -$41.4M | -$35.9M | -$72.7M | -$72.7M | -$118.8M |
| EPS (diluted) | $-0.39 | $-0.37 | $-0.37 | $-0.46 | $-0.42 | $-1.07 | $-1.07 | $-1.75 |
| EPS (basic) | $-0.39 | $-0.37 | $-0.37 | $-0.46 | $-0.42 | $-1.07 | $-1.07 | $-1.75 |
| Operating margin | — | — | — | — | — | -$18.2K | $7.5K | -$138 |
| Net margin | — | — | — | — | — | -$17.5K | $7.1K | -$134 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $264.6M | $293.6M | $332.6M | $362.7M | $194.6M | $219.7M | $193.6M | $250.7M |
| Total liabilities | $25.4M | $20.4M | $27.4M | $30.7M | $26.7M | $18.3M | $28.9M | $54.5M |
| Stockholders' equity | $239.2M | $273.2M | $305.3M | $332.0M | $167.9M | $201.4M | $164.8M | $196.2M |
| Total current assets | $256.3M | $285.0M | $323.7M | $353.4M | $186.9M | $216.1M | $189.4M | $245.3M |
| Total current liabilities | $21.1M | $16.0M | $22.7M | $25.8M | $21.4M | $17.9M | $28.4M | $53.9M |
| Cash & equivalents | $49.3M | $229.1M | $226.7M | $225.2M | $58.1M | $59.8M | $77.4M | $71.8M |
| Marketable securities (current) | $201.4M | $50.6M | $90.3M | $118.8M | $122.7M | $144.3M | $99.1M | $162.6M |
| Accounts receivable | — | — | $88.0K | $132.0K | $103.0K | $300.0K | $447.0K | $1.7M |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $199.0K | $212.0K | $310.0K | $399.0K | $445.0K | $816.0K | $961.0K | $1.3M |
| Other non-current assets | — | $2.5M | $2.5M | $2.5M | — | $11.0K | $24.0K | $482.0K |
| Accounts payable | $5.5M | $3.5M | $3.5M | $5.3M | $3.3M | $4.8M | $2.9M | $1.5M |
| Accrued liabilities | $14.6M | $11.3M | $17.9M | $19.5M | $17.5M | $12.1M | $23.9M | $50.5M |
| Common stock & paid-in capital | $11.0K | $11.0K | $11.0K | $11.0K | $9.0K | $9.0K | $7.0K | $7.0K |
| Retained earnings | -$836.1M | -$792.7M | -$751.4M | -$718.4M | -$684.0M | -$642.6M | -$606.7M | -$569.1M |
| Accumulated other comprehensive income (loss) | $19.0K | $240.0K | $404.0K | $815.0K | $551.0K | $0 | -$92.0K | $641.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.4M | -$36.9M | -$27.9M | -$30.4M | -$25.2M | -$39.8M | -$59.0M | -$41.6M |
| Investing cash flow | -$149.8M | $36.3M | $29.5M | $5.2M | $23.0M | -$43.7M | $65.0M | $38.8M |
| Financing cash flow | $1.5M | $3.2M | -$208.0K | $191.6M | -$31.0K | $65.7M | $110.0K | $80.0K |
| Free cash flow | -$31.5M | — | -$28.0M | -$30.4M | -$25.3M | -$39.8M | -$59.0M | -$41.6M |
| Capital expenditures | $30.0K | — | $86.0K | $24.0K | $17.0K | $11.0K | $20.0K | -$19.0K |
| Share-based compensation | $8.3M | $6.1M | $6.4M | $7.1M | $7.3M | $6.8M | $6.7M | $6.8M |
| Change in accounts receivable | — | — | -$44.0K | $30.0K | -$198.0K | -$147.0K | -$1.3M | -$2.4M |
| Change in inventory | — | — | — | — | — | $0 | $0 | $0 |
| Change in accounts payable | $2.0M | $10.0K | $275.0K | -$33.0K | -$1.5M | $1.9M | $1.5M | -$3.5M |
| Purchases of investments | $180.8M | $19.7M | $30.4M | $58.7M | $39.0M | $103.6M | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | — |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M | -$87.9M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
| EPS (basic) | $-1.53 | $-4.43 | $0.73 | $-3.39 | $-13.35 |
| Operating margin | — | -$360 | $10 | -$906 | — |
| Net margin | — | -$345 | $13 | -$892 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M |
| Stockholders' equity | $305.3M | $164.8M | $433.4M | $340.6M | -$151.2M |
| Total current assets | $323.7M | $189.4M | $464.7M | $382.1M | $105.0M |
| Total current liabilities | $22.7M | $28.4M | $82.0M | $46.6M | $17.4M |
| Cash & equivalents | $226.7M | $77.4M | $170.2M | $62.5M | $50.2M |
| Marketable securities (current) | $90.3M | $99.1M | $201.2M | — | — |
| Accounts receivable | $88.0K | $447.0K | $40.0M | $15.3M | — |
| Inventory | — | — | $38.3M | $9.8M | — |
| Property, plant & equipment | $310.0K | $961.0K | $2.7M | $2.6M | $474.0K |
| Other non-current assets | — | $24.0K | $701.0K | $466.0K | — |
| Accounts payable | $3.5M | $2.9M | $22.1M | $6.3M | $4.4M |
| Accrued liabilities | $17.9M | $23.9M | $57.7M | $38.3M | — |
| Common stock & paid-in capital | $11.0K | $7.0K | $7.0K | $7.0K | $1.0K |
| Retained earnings | -$751.4M | -$606.7M | -$304.9M | -$354.2M | -$155.8M |
| Accumulated other comprehensive income (loss) | $404.0K | -$92.0K | $197.0K | -$86.0K | $9.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$123.3M | -$167.6M | $11.9M | -$179.9M | -$74.8M |
| Investing cash flow | $14.0M | $75.7M | $92.1M | -$239.0M | -$46.4M |
| Financing cash flow | $257.0M | $348.0K | $3.5M | $431.8M | $158.5M |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M | -$75.2M |
| Capital expenditures | $138.0K | $157.0K | $1.2M | $2.5M | $353.0K |
| Share-based compensation | $27.6M | $33.0M | $37.2M | $21.7M | $3.1M |
| Change in accounts receivable | -$359.0K | -$39.6M | $24.7M | $15.3M | — |
| Change in inventory | — | $9.3M | $73.1M | $9.8M | — |
| Change in accounts payable | $580.0K | -$19.1M | $15.9M | $1.9M | $670.0K |
| Purchases of investments | $231.8M | $232.0M | $300.8M | $415.9M | $49.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AMLX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-02 to 2026-10-05
Recent transactions
- Insiders have net sold 147,502 shares over the last 182 days, across 1 purchase and 13 sales.
- Most recent: MILNE GEORGE M JR (Reporting person) — Open market sale of 30,000 shares on 2026-10-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)3,800 sh(1 txns)
Sales (open market)151,302 sh(13 txns)
Net Shares-147,502
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| MILNE GEORGE M JR | Reporting person | Open market sale | 2026-10-05 | 30,000 |
| Bedrosian Camille L | Chief Medical Officer | Open market sale | 2026-09-10 | 7,947 |
| FRATES JAMES M | Chief Financial Officer | Open market sale | 2026-09-10 | 9,768 |
| Mazzariello Gina | Chief Legal Officer | Open market sale | 2026-09-10 | 9,525 |
| Klee Justin B. | Co-Chief Executive Officer | Open market sale | 2026-09-10 | 29,025 |
| Cohen Joshua B | Co-Chief Executive Officer | Open market sale | 2026-09-10 | 29,545 |
| Firestone Karen | Reporting person | Option exercise | 2026-08-31 | 25,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-05 | MILNE GEORGE M JR | Reporting person | Open market sale | 30,000 | $27.70 |
| 2026-09-10 | Bedrosian Camille L | Chief Medical Officer | Open market sale | 7,947 | $32.21 |
| 2026-09-10 | Bedrosian Camille L | Chief Medical Officer | Open market sale | 2,081 | $33.09 |
| 2026-09-10 | FRATES JAMES M | Chief Financial Officer | Open market sale | 9,768 | $32.27 |
| 2026-09-10 | FRATES JAMES M | Chief Financial Officer | Open market sale | 1,042 | $33.23 |
| 2026-09-10 | Mazzariello Gina | Chief Legal Officer | Open market sale | 9,525 | $32.46 |
| 2026-09-10 | Mazzariello Gina | Chief Legal Officer | Open market sale | 11 | $33.34 |
| 2026-09-10 | Klee Justin B. | Co-Chief Executive Officer | Open market sale | 29,025 | $32.13 |
| 2026-09-10 | Klee Justin B. | Co-Chief Executive Officer | Open market sale | 1,439 | $33.16 |
| 2026-09-10 | Cohen Joshua B | Co-Chief Executive Officer | Open market sale | 29,545 | $32.16 |
| 2026-09-10 | Cohen Joshua B | Co-Chief Executive Officer | Open market sale | 919 | $33.15 |
| 2026-08-31 | Firestone Karen | Reporting person | Option exercise | 25,000 | $1.76 |
| 2026-08-31 | Firestone Karen | Reporting person | Option exercise | 25,000 | $5.05 |
| 2026-08-18 | FRATES JAMES M | Chief Financial Officer | Grant / award | 22,807 | $0.00 |
| 2026-08-18 | Klee Justin B. | Co-Chief Executive Officer | Grant / award | 60,039 | $0.00 |
| 2026-08-18 | Mazzariello Gina | Chief Legal Officer | Grant / award | 21,284 | $0.00 |
| 2026-08-18 | Bedrosian Camille L | Chief Medical Officer | Grant / award | 22,807 | $0.00 |
| 2026-08-18 | Cohen Joshua B | Co-Chief Executive Officer | Grant / award | 60,039 | $0.00 |
| 2026-07-10 | Mazzariello Gina | Chief Legal Officer | Open market sale | 15,000 | $17.61 |
| 2026-07-09 | Mazzariello Gina | Chief Legal Officer | Open market sale | 15,000 | $18.32 |
| 2026-05-21 | Firestone Karen | Reporting person | Open market purchase | 3,800 | $13.51 |
| 2026-03-05 | Cohen Joshua B | Co-Chief Executive Officer | Grant / award | 248,865 | $0.00 |
| 2026-03-05 | Mazzariello Gina | Chief Legal Officer | Grant / award | 74,660 | $0.00 |
| 2026-03-05 | FRATES JAMES M | Chief Financial Officer | Grant / award | 95,990 | $0.00 |
| 2026-03-05 | Klee Justin B. | Co-Chief Executive Officer | Grant / award | 248,865 | $0.00 |
| 2026-03-05 | Bedrosian Camille L | Chief Medical Officer | Grant / award | 95,990 | $0.00 |
| 2026-03-02 | Klee Justin B. | Co-Chief Executive Officer | Open market sale | 29,282 | $14.47 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:16 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
Recent news
Headlines about AMLX (Amylyx Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
AMLX 261120 45.00C (AMLX261120C45000) Stock Options Chain | Quotes & News
Moomoo · 2026-10-19 -
AMLX 261016 28.00P (AMLX261016P28000) Stock Options Chain | Quotes & News
Moomoo · 2026-10-18 -
Why Is AMLX Stock Popping 14% After Hours?
Stocktwits · 2026-10-18 -
AMLX261016C00034000 interactive stock chart | AMLX Oct 2026 34.000 call stock
Yahoo Finance Australia · 2026-10-18 -
Behavioral Patterns of AMLX and Institutional Flows
Stock Traders Daily · 2026-10-18 -
AMLX Oct 2026 46.000 put (AMLX261016P00046000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-17 -
AMLX261016P00046000 interactive stock chart | AMLX Oct 2026 46.000 put stock
Yahoo Finance Australia · 2026-10-17 -
AMLX Oct 2026 32.000 call (AMLX261016C00032000) interactive stock chart
Yahoo Finance UK · 2026-10-16
No headlines in this category right now — try “All”.